![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 14, 2021 3:42:42 PM
An audio interview of interest to RLFTF investors conducted on November 9, 2020, with the editors of New England Journal of Medicine. They discuss the EUA and Accelerated Approval processes in the scope of COVID therapeutic trials. Interesting discussion regarding the importance of trial sizes, the challenges of treating COVID across the disease stages as well as Dr Woodcocks experience with therapeutics. You can listen to this audio without subscribing to NEJM.
https://www.nejm.org/action/showMediaPlayer?doi=10.1056%2FNEJMdo005917&aid=10.1056%2FNEJMe2033111&area=
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM